ライフサイエンスコーパス: CGM

1 CGM bias varied by postprandial test such that GI for 50

2 CGM data came from 24 of the multiple sclerosis (mean ag

3 CGM data for weeks 3-8 of the interventions were analyse

4 CGM data were collected from two inpatient feeding studi

5 CGM demonstrated lower mean glucose and more time in ran

6 CGM devices include a fine sensor inserted under the ski

7 CGM overestimated glycemic responses in numerous context

8 CGM should be offered to all pregnant women with type 1

9 CGM use had lower point estimates for hypoglycemia hospi

10 CGM use in a primary care setting compared to usual care

11 CGM use was associated with a significantly greater redu

12 CGM users experienced the greatest reductions at approxi

13 CGM were impregnated with 50,000 keratinocytes per cm2,

14 CGM, TGM, and TGW had comparable TFV-DP concentrations i

15 CGM, TGM, and TGW had comparable TFV-DP concentrations i

16 CGM-derived glycemic traits were calculated using the "c

17 CGM-estimated fasting and postprandial glucose concentra

18 CGMs were implanted in mice, and sensor versus blood glu

19 following: CGM Cr (r(s) = 0.524, P = 0.009), CGM Glx (r(s) = 0.580, P = 0.003) and NAWM Ins (r(s) = -

20 4 [CGM]; P = 0.03 [WCER]) and 2 y (P = 0.02 [CGM]; P = 0.01 [WCER]) using these 2 RRs.

21 arger than in Abeta- scans at 1 y (P = 0.04 [CGM]; P = 0.03 [WCER]) and 2 y (P = 0.02 [CGM]; P = 0.01

22 At a significance level of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all signifi

23 reater glycemic control as indicated by >/=1 CGM variable was associated with higher Healthy Eating I

24 skin reactions occurring in 49 (48%) of 103 CGM participants and eight (8%) of 104 control participa

25 comprised of 17 cisgender women (CGW) and 15 CGM.

26 comparable severe hypoglycaemia episodes (18 CGM and 21 control) and time spent hypoglycaemic (3% vs

27 ts in the planning pregnancy trial (two [4%] CGM and one [2%] control).

28 ination of alternative protein sources (2.5% CGM, 5% SFM, and 7.5% DDGS) until 35 days of age.

29 pants during pregnancy and in 23 (44%) of 52 CGM participants and five (9%) of 57 control participant

30 ticipants in the pregnancy trial (eight [7%] CGM, five [5%] control) and in three (3%) participants i

31 tistically significant differences for all 9 CGM metrics, 6 of 7 HbA1c outcomes, and none of the 15 c

32 nces in 3 of 7 binary HbA1c outcomes, 8 of 9 CGM metrics, and 1 of 4 patient-reported outcomes.

33 A CGM that resists fibrous encapsulation would better appr

34 on of glucose into the tissue deposited on a CGM is substantially delayed relative to interstitial fl

35 had lower multivariable odds of receiving a CGM prescription than White or insured adults, respectiv

36 ntification of metabolic subphenotypes via a CGM may aid the risk stratification of individuals with

37 00037) and a lower proportion of time with a CGM-measured glucose concentration below 3.3 mmol/L on d

38 centration and the proportion of time with a CGM-measured glucose concentration below 3.3 mmol/L, on

39 ablished protocols; participants also wore a CGM device during the control period.

40 ied secondary outcomes, including additional CGM metrics for hypoglycemia, hyperglycemia, and glucose

41 ted how different test foods/beverages alter CGM accuracy.

42 3]; EDSS >=3.5: 1.30 +/- 0.04 [P = .01]) and CGM (marginal mean +/- standard error, healthy controls:

43 5, 1.39)], HOMA2-%B [1.11 (1.01, 1.22)], and CGM-based measures, including mean glucose [1.05 (1.00,

44 ic fungal pathogens to the control of CM and CGM and to the recovery of cassava yield across the vast

45 indicate that metabolite changes in NAWM and CGM can be detected early in the clinical course of mult

46 NAWM and CGM metabolite concentrations estimated were: choline-co

47 to 12%; P=0.47), comparable between TGW and CGM (mean difference -12%; 95% CI -27% to 7%; P=0.21) an

48 of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all significantly reduced, and NAWM Ins was

49 As CGM usage extends beyond type 1 diabetes, there is growi

50 The most commonly available CGMs are limited by the physiology of the subcutaneous s

51 ating the sensors of a phosphorescence based CGM system into a standard insulin infusion set.

52 responses were relatively discordant between CGMs, with a mean Kendall rank correlation coefficient o

53 te, postprandial overestimate of glycemia by CGM.

54 in 1966 [Egyptian Geological Museum, Cairo (CGM) 40237] reveal that previous estimates of its endocr

55 icipants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood glucose m

56 t a significance level of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all significantly re

57 omparable to that of state-of-art commercial CGM systems.

58 he surfaces of FDA-approved human commercial CGM needle-type implanted sensors in a rodent subcutaneo

59 le-port system is comparable with commercial CGM systems but further improvements are needed.

60 urised and is now comparable with commercial CGM systems regarding size, weight and wear comfort.

61 Drug-releasing and control CGM implants were compared in murine percutaneous implan

62 period compared to blank microsphere control CGM implants.

63 All other multiplicity-controlled CGM outcomes reflective of hyperglycemia that were measu

64 Centers with full reimbursement for CSII, CGM, glucometers, and insulin showed mean HbA1c levels o

65 However, current CGM devices need further miniaturization and improved fu

66 However, it is unknown whether different CGM devices result in concordant meal rankings according

67 otential benefits and limitations of digital CGM systems.

68 ing meals ranked according to the discordant CGM was inversely correlated with each subject's Kendall

69 ement) and factors contributing to disrupted CGM use (e.g., changes in insurance coverage, issues wit

70 During CGM, average percent time in hyperglycemic and hypoglyce

71 articipants were randomly assigned to either CGM in addition to capillary glucose monitoring or capil

72 ased MPhi recruitment significantly enhanced CGM performance when compared to control mice.

73 n sites, which led to significantly enhanced CGM performance, when compared to normal mice.

74 and suggest chemokine targets for enhancing CGM in vivo.

75 Existing CGM-based approaches do not account for sensor error, wh

76 Expanding CGM to these groups could minimize hypoglycaemia while a

77 s sought to reduce sensor fibrosis to extend CGM functional lifetimes in subcutaneous sites.

78 arietal organoleptic traits of the fermented CGM.

79 trations were significant for the following: CGM Cr (r(s) = 0.524, P = 0.009), CGM Glx (r(s) = 0.580,

80 For CGM-based glycemic variability outcomes (standard deviat

81 -) and 1.36 +/- 1.98 (Abeta+) (P = 0.02) for CGM and 0.13 +/- 1.47 and 1.32 +/- 1.75 (P = 0.01), resp

82 ge, indicating its potential application for CGM systems.

83 Associations were more consistent for CGM variables obtained concurrently with dietary intake

84 type 1 diabetes; observational evidence for CGM in patients with insulin-treated type 2 diabetes is

85 ntral, physiologically stable body space for CGM: the intraperitoneal space.

86 lectrical current was measured directly from CGM electrodes to define sensor kinetics in the absence

87 ndard deviation of glucose (SD glucose) from CGM and continuous overlapping net glycemic action using

88 ements in non-glycaemic health outcomes from CGM use.

89 roperly distanced reference strains generate CGMs that accurately depict evolutionary relationships,

90 roperly distanced reference strains generate CGMs that distort and reroot outgroups.

91 sis disease effects on NAWM and cortical GM (CGM) metabolite concentrations, and the relationships be

92 We collected the current from the grounded CGM probe while scanning a periodically poled lithium ni

93 Higher CGM TSC was independently associated with Expanded Disab

94 EJL(first) >1-h was associated with higher CGM-based mean amplitude of glycemic excursions (MAGE) [

95 However, CGM-independent data suggest rapid equilibration of inte

96 therefore enable less invasive and improved CGM in patients affected by diabetes.

97 Sodium accumulation in CGM reflects underlying neuroaxonal metabolic abnormalit

98 lants exhibited no significant difference in CGM fibrosis at implant sites but showed relatively stab

99 Furthermore, differences in CGM compared with capillary fasting glucose concentratio

100 Disparities in CGM orders were observed among patients reporting Hispan

101 and access to CGM may reduce disparities in CGM uptake and improve diabetes outcomes.

102 emia/ketosis (1 participant with an event in CGM group and 4 in the BGM group), and diabetic ketoacid

103 associated with significant improvements in CGM metrics in PWD who had suboptimal glucose control at

104 g/dL [10.0 mmol/L]), but also an increase in CGM-measured hypoglycaemia (p=0.0001 for <70 mg/dL [<3.9

105 The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes.

106 e feasibility of improved miniaturization in CGM based on microfluidics.

107 M plus CSII group had a greater reduction in CGM-measured mean glucose (p=0.005) and hyperglycaemia (

108 eeded to understand the causes of infrequent CGM orders in FQHCs and drivers of observed disparities

109 nical research program that aims to initiate CGM within 1 month of T1D diagnosis.

110 Insulin pump therapy with integrated CGM and a suspend-before-low feature reduced the frequen

111 To investigate CGM-based phylogenies, we devised computer models to sim

112 This ionized CGM contains a substantial mass of heavy elements and ga

113 currently with the use of the Medtronic iPro CGM system.

114 accurately control the blood glucose level, CGM should be stable and accurate for a long period.

115 tes, there is growing interest in leveraging CGM data for clinical decision-making.

116 Several combination device strategies load CGM sensors with drug payloads that release locally to t

117 is using these "comparative-genome markers" (CGMs) produced a highly unusual phylogeny with a complet

118 acterized collagen-glycosaminoglycan matrix (CGM) that has been shown to function as a dermal analog

119 calculated the TSC in cortical grey matter (CGM), deep grey matter, normal-appearing white matter (W

120 Four RRs (cerebellar gray matter [CGM], whole cerebellum [WCER], pons, and subcortical whi

121 The time to half-maximum CGM response in vitro was 35 +/- 2 s.

122 ding sunflower meal (SFM), corn gluten meal (CGM), and dried distillers' grains with solubles (DDGS)

123 Mean CGM use was 6.7 days per week (SD 0.8) in the CGM plus C

124 reas period was associated with a lower mean CGM-measured glucose concentration on days 2-5 than was

125 The mean CGM glucose concentration was 7.8 mmol/L (SD 0.6) in the

126 s, analysed by intention to treat, were mean CGM-measured glucose concentration and the proportion of

127 The circumgalactic medium (CGM) is fed by galaxy outflows and accretion of intergal

128 nizing hormones compared with cisgender men (CGM).

129 A charge gradient microscopy (CGM) probe was used to collect surface screening charges

130 on charges using charge gradient microscopy (CGM).

131 esign of those clinical trials where minimal CGM monitoring duration is crucial in cost-effectiveness

132 P consisted of a continuous glucose monitor (CGM) and insulin pump connected to a modified smartphone

133 Continuous glucose monitor (CGM) devices enable characterization of individuals' gly

134 Continuous glucose monitor (CGM) readings are delayed relative to blood glucose, and

135 imes/day or uses continuous glucose monitor (CGM); (2) gives at least 3 rapid-acting insulin boluses

136 ssessed using continuous glucose monitoring (CGM) (n = 16), and prospective observational study compa

137 Continuous glucose monitoring (CGM) allows patients with diabetes to manage critical di

138 th integrated continuous glucose monitoring (CGM) and a suspend-before-low feature (Medtronic MiniMed

139 ombination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be

140 (HYPOscore), continuous glucose monitoring (CGM) and in 8 subjects measurements of glucose variabili

141 ombination of continuous glucose monitoring (CGM) and insulin infusion.

142 Although continuous glucose monitoring (CGM) and insulin pumps are moving toward a closed-loop s

143 Continuous glucose monitoring (CGM) data have revolutionized the management of type 1 d

144 nd 18; masked continuous glucose monitoring (CGM) data were obtained concurrently with the use of the

145 Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but publishe

146 d data from a continuous glucose monitoring (CGM) device to control subcutaneous delivery of insulin

147 Continuous glucose monitoring (CGM) devices allow real-time glucose readings leading to

148 Although continuous glucose monitoring (CGM) devices are now considered the standard of care for

149 ew-generation continuous glucose monitoring (CGM) devices capable of in vivo monitoring of glucose di

150 Continuous glucose monitoring (CGM) devices have demonstrated efficacy in adults and mo

151 and time with continuous glucose monitoring (CGM) glucose concentration less than 3.3 mmol/L, analyse

152 Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with typ

153 Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adult

154 iabetes using continuous glucose monitoring (CGM) has not been studied.

155 he benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly

156 Continuous glucose monitoring (CGM) is an important aid for diabetic patients to optimi

157 Continuous glucose monitoring (CGM) is associated with improvements in hemoglobin A1c (

158 biosensor for continuous glucose monitoring (CGM) is presented.

159 Continuous glucose monitoring (CGM) is recommended for patients with type 1 diabetes; o

160 Using a Continuous Glucose Monitoring (CGM) murine model we previously demonstrated that geneti

161 ectiveness of continuous glucose monitoring (CGM) on maternal glucose control and obstetric and neona

162 Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and

163 Continuous glucose monitoring (CGM) sensors are often advocated as a clinical solution

164 a recorded by continuous glucose monitoring (CGM) sensors, but the duration of CGM recording guarante

165 A continuous glucose monitoring (CGM) system consisting of a wireless, subcutaneously imp

166 Continuous glucose monitoring (CGM) systems are most important in the current Type I di

167 Digital continuous glucose monitoring (CGM) systems may allow real-time glucose monitoring with

168 Continuous glucose monitoring (CGM) technologies enable frequent sensing of glucose to

169 Continuous glucose monitoring (CGM) technology has improved and the devices are more wi

170 The advent of continuous glucose monitoring (CGM) technology now allows real time monitoring of blood

171 ean and SD of continuous glucose monitoring (CGM) values, percentage of CGM values in euglycemic and

172 ally-invasive continuous glucose monitoring (CGM) which offers real-time information about interstiti

173 C), combining continuous glucose monitoring (CGM) with insulin pump (continuous subcutaneous insulin

174 glycemia from continuous glucose monitoring (CGM), beta cell secretory responses from a glucose-poten

175 ogies such as continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (insulin

176 Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults

177 Continuous glucose monitors (CGM) are used to characterize postprandial glycemia, yet

178 Continuous glucose monitors (CGM) provide valuable insights about glycemic control th

179 Continuous glucose monitors (CGMs) are used to characterize postprandial glucose resp

180 Continuous glucose monitors (CGMs) have shown promise in diabetes management, yet the

181 Continuous glucose monitors (CGMs) offer real-time assessment of glucose concentratio

182 as measured by continuous glucose monitors (CGMs).

183 fermentation of the concentrated grape must (CGM) from cv. Xinomavro using the best-performing indige

184 surements on 10 patients showed that the NIR-CGM sensor data reflects the blood reference values adeq

185 s in the pregnancy trial, and in 12 (27%) of CGM participants and 21 (37%) of control participants in

186 Adverse events occurred in 51 (48%) of CGM participants and 43 (40%) of control participants in

187 The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week.

188 s-specifically the speed and acceleration of CGM time series-as new biomarkers for predicting long-te

189 We found no apparent benefit of CGM in women planning pregnancy.

190 MDI or switch to CSII, with continuation of CGM, for 28 weeks.

191 onitoring (CGM) sensors, but the duration of CGM recording guaranteeing a reliable indicator is under

192 To determine the effectiveness of CGM in adults with type 1 diabetes treated with insulin

193 To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple da

194 examined 1) interindividual heterogeneity of CGM bias compared with criterion and 2) whether CGM bias

195 This study sought to determine the loci of CGM delays.

196 ications were associated with higher odds of CGM prescription.

197 ucose monitoring (CGM) values, percentage of CGM values in euglycemic and hyperglycemic ranges, and m

198 ultiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decre

199 INTERPRETATION: Use of CGM during pregnancy in patients with type 1 diabetes is

200 All eligible participants were offered CGM within 1 month of diabetes diagnosis.

201 cose and median percent time hypoglycemic on CGM were unchanged with CSII, SD glucose and CONGA4 redu

202 Validation is performed on CGM data of 148 subjects with type-1-diabetes.

203 tcomes, including additional HbA1c outcomes, CGM glucose metrics, and patient-reported outcomes with

204 range (sCTR), designed to augment pump plus CGM by preventing extreme glucose excursions; and enhanc

205 Pregnant CGM users spent more time in target (68% vs 61%; p=0.003

206 ir blood glucose levels, and having no prior CGM use were included.

207 Each participant wore a Dexcom G6 Pro CGM for approximately 10 days.

208 m G4 Platinum and Abbott Freestyle Libre Pro CGMs during 28 inpatient days in 16 adults without diabe

209 d minimally invasive device that can provide CGM is essential for monitoring the health conditions of

210 a duration of at least 6 months who provided CGM data between January 1, 2016, and December 31, 2021.

211 For glycemic control, rt-CGM is superior to SMBG and sensor-augmented insulin pum

212 Compared with SMBG, rt-CGM achieved a lower HbA1c level (between-group differen

213 5% CI, 18.0%-24.1%]), intermittently scanned CGM plus injection use (12.5% [95% CI, 10.7%-14.4%]), an

214 I, 10.7%-14.4%]), and intermittently scanned CGM plus insulin pump use (11.3% [95% CI, 9.2%-13.8%]) (

215 n-subject meal rankings between simultaneous CGM devices.

216 we unpack factors contributing to sustained CGM use (e.g., easier and better blood glucose managemen

217 red by continuous glucose monitoring system (CGM); the second is a model of diabetes parameter regres

218 We envision that CGM can be used in high-speed ferroelectric domain imagi

219 We found that CGMs represent a distinct class of phylogenetic markers

220 The CGM data were used to map the local electric current ori

221 The CGM group averaged 6.7 days (SD, 0.9) of CGM use per wee

222 tion, local masitinib penetration around the CGM to several hundred microns sought to reduce sensor f

223 are within-subject meal rankings between the CGM devices according to their incremental glucose respo

224 during 6 in-clinic sessions by comparing the CGM glucose values to venous blood glucose measurements

225 most commonly reported adverse events in the CGM and BGM groups were severe hypoglycemia (3 participa

226 1.1% at 12 weeks and 1.0% at 24 weeks in the CGM group and 0.5% and 0.4%, respectively, in the contro

227 cidosis (3 participants with an event in the CGM group and 1 in the BGM group).

228 lycemia (3 participants with an event in the CGM group and 2 in the BGM group), hyperglycemia/ketosis

229 Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adj

230 8.9% at baseline and 8.5% at 26 weeks in the CGM group and 8.9% at both baseline and 26 weeks in the

231 Mean HbA1c decreased in the CGM group compared with the standard BGM group (adjusted

232 trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial were randomly assigned vi

233 (39 minutes per day) during follow-up in the CGM group vs 4.7% (68 minutes per day) and 4.9% (70 minu

234 n <70 mg/dL was 43 min/d (IQR, 27-69) in the CGM group vs 80 min/d (IQR, 36-111) in the control group

235 In the CGM group, 68% of participants used CGM at least 5 days

236 In the CGM group, 93% used CGM 6 d/wk or more in month 6.

237 0.3% (SD 0.9; 3.3 mmol/mol [SD 9.8]) in the CGM plus CSII group and 0.1% (0.4; 1.1 mmol/mol [4.4]) i

238 pleted by 36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in t

239 GM use was 6.7 days per week (SD 0.8) in the CGM plus CSII group and 6.9 days per week (0.3) in the C

240 mmol/L) was 791 min per day (SD 157) in the CGM plus CSII group and 741 min per day (225) in the CGM

241 Participants in the CGM plus CSII group had a greater reduction in CGM-measu

242 No participants in the CGM plus CSII group who completed the trial discontinued

243 emia occurred in one participant each in the CGM plus CSII group.

244 CSII group and 741 min per day (225) in the CGM plus MDI group (adjusted mean treatment group differ

245 up and 0.1% (0.4; 1.1 mmol/mol [4.4]) in the CGM plus MDI group (p=0.32).

246 SII group and 6.9 days per week (0.3) in the CGM plus MDI group (p=0.86).

247 glycaemia occurred in one participant in the CGM plus MDI group, and diabetic ketoacidosis and severe

248 group and 35 (92%) of 38 participants in the CGM plus MDI group.

249 cells, fibroblasts, and macrophages into the CGM from the underlying wound bed, resulting in formatio

250 fluorescent glucose analog (2-NBDG) into the CGM microenvironment was observed in vivo using intravit

251 this degradation mechanism is mitigated, the CGM technique can be applied to efficient energy harvest

252 Gradually, the stromal cellularity of the CGM decreased and collagen deposition and remodeling inc

253 acellular matrix, and the degradation of the CGM fibers, respectively.

254 liraglutide daily beginning at day 39 of the CGM monitoring period.

255 Complete dissolution of the CGM occurred, partly as a result of degradation by an on

256 in being supplied is calculated based on the CGM results.

257 ndurance of charge collection by rubbing the CGM tip on the polymer film was limited to 20 scan cycle

258 Bland-Altman analysis demonstrated that the CGM underestimated the 8-h gold-standard glucose rise by

259 7 participants were randomly assigned to the CGM plus CSII group and 38 participants were randomly as

260 8 participants were randomly assigned to the CGM plus MDI group.

261 Applying this understanding to the CGM-based phylogeny of M. tuberculosis, we found evidenc

262 s the TBR estimation error variance with the CGM recording length.

263 hanges in outcomes associated with real-time CGM initiation, estimated using a difference-in-differen

264 95% CI, 33.9%-38.4%]), followed by real-time CGM plus injection use (20.9% [95% CI, 18.0%-24.1%]), in

265 e in range target was highest with real-time CGM plus insulin pump use (36.2% [95% CI, 33.9%-38.4%]),

266 ed time in range was highest among real-time CGM plus insulin pump users (64.7% [95% CI, 62.6%-66.7%]

267 cutaneous insulin infusion without real-time CGM.

268 Random assignment 2:1 to CGM (n = 105) or usual care (control group; n = 53).

269 Early initiation of and access to CGM may reduce disparities in CGM uptake and improve dia

270 Random assignment to CGM (n = 79) or usual care (control group, n = 79).

271 th public insurance face greater barriers to CGM access.

272 rror Grid Analysis showed similar results to CGM-devices currently on the market.

273 lly integrated using automated data transfer CGM-->algorithm-->CSII.

274 Participants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood gluc

275 patients with type 2 diabetes currently use CGM, these results support an additional management meth

276 were randomly assigned in a 1:1 ratio to use CGM (n = 103) or standard BGM (n = 100).

277 Precision nutrition approaches that use CGMs to personalize meal recommendations for minimizing

278 use; mean HbA1c, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6.

279 In the CGM group, 93% used CGM 6 d/wk or more in month 6.

280 insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had

281 In the CGM group, 68% of participants used CGM at least 5 days per week in month 6.

282 (0.71) increase in TIR among those who used CGMs.

283 to CSII in adults with type 1 diabetes using CGM.

284 lycemic responses to test foods/drinks using CGM compared with capillary sampling (criterion).

285 most commonly reported adverse events using CGM and standard BGM, respectively, were severe hypoglyc

286 r relative glycemic responses to foods using CGM, and capillary sampling should be prioritized for ac

287 difference in HbA1c in pregnant women using CGM (mean difference -0.19%; 95% CI -0.34 to -0.03; p=0.

288 In vivo, CGMs took 24 +/- 7 min to reach maximum current versus 2

289 The primary outcome was CGM-measured percentage of time that sensor glucose valu

290 The primary outcome was CGM-measured time in the glucose concentration range of

291 raz app users who had diabetes, were wearing CGM, and used Karaz app for >= 3 months were retrospecti

292 bias compared with criterion and 2) whether CGM bias could be improved with adjustment for baseline

293 lly available fruit smoothie was higher with CGM (69; 95% confidence interval: 48, 99) compared with

294 The correlation of clinical impairment with CGM Cr and Glx but not tNAA suggests that it is more clo

295 lycemia at less than 70 mg/dL, measured with CGM for 7 days at 12 and 24 weeks.

296 gnancy) to capillary glucose monitoring with CGM (108 pregnant and 53 planning pregnancy) or without

297 healthy and six diabetic rhesus monkeys with CGM probes in the carotid artery and collected glucose v

298 I 0.7-1.6; p<0.0001), and the mean time with CGM glucose concentration less than 3.3 mmol/L was 0.6%

299 ple daily insulin injections with or without CGM) or the intervention group for HCL therapy.

300 ursions differ between 2 simultaneously worn CGMs.